Equities

LungLife AI Inc

LLAI:LSE

LungLife AI Inc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)11.50
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change-87.57%
  • Beta--
Data delayed at least 20 minutes, as of Sep 26 2024 10:27 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Oct-23
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
  • 26-Sep-24
Select bar for recommendation details.
Recommendations26-Sep-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast

The 2 analysts offering 12 month price targets for LungLife AI Inc have a median target of 199.63, with a high estimate of 228.79 and a low estimate of 170.47. The median estimate represents a 1,635.94% increase from the last price of 11.50.
High1,889.5%228.79
Med1,635.9%199.63
Low1,382.4%170.47

Earnings history & estimates

LungLife AI Inc reported annual 2023 losses of -0.21 per share on Apr 04, 2024.
Average growth rate+27.52%
More ▼

Revenue history & estimates

LungLife AI Inc had revenues for the full year 2023 of 46.00k. This was 91.67% above the prior year's results.
Average growth rate+1.96%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.